Safety and efficacy of telitacicept in refractory childhood-onset systemic lupus erythematosus: A self-controlled before-after trial.

Li SunQian ShenYinv GongYifan LiQianying LvHaimei LiuFei ZhaoHaiguo YuLingzhi QiuXiaozhong LiXiaoliang HeYuqing ChenZhiquan XuHong Xu

Published in: Lupus (2022)

Telitacicept combined with the standard treatment may significantly increase the SRI-4 response rate and reduce the glucocorticoid dosage in refractory cSLE, and also shown efficacy on lupus nephritis. The related adverse drug events were controllable.

Keyphrases

adverse drug
systemic lupus erythematosus
clinical trial
electronic health record
emergency department
study protocol
disease activity
phase iii
drug induced
randomized controlled trial
phase ii
young adults
combination therapy
open label
smoking cessation